Fangxia Wang

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wanhong Zhao, Jie Liu, Baiyan Wang et al. · Journal of Hematology & Oncology · 2018 · 526 citations · Full text

Immunology, Immunodominance, Immunotherapeutics +19

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Wanhong Zhao, Baiyan Wang, Lijuan Chen et al. · Journal of Hematology & Oncology · 2022 · 139 citations · Full text

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang et al. · Frontiers of Medicine · 2019 · 106 citations

Inflammation, Autoimmune Disease, T-regulatory Cell +7

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Baiyan Wang, Wanhong Zhao, Jie Liu et al. · Blood · 2019 · 91 citations

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Frank Fan, Wanhong Zhao, Jie Liu et al. · Journal of Clinical Oncology · 2017 · 79 citations

Cell Therapy, Immunology, Pathology +22